Unlabelled: Thyroid hormones are an important regulator of cardiac function and vascular system. Atrial fibrillation is a common cardiac arrhythmia and an important risk factor for the ischemic cerebral vascular accident and heart failure.
Objectives: The examination of the risk to develop atrial fibrillation in relation to the whole spectrum of thyroid dysfunctions.
Material And Methods: All participants to our study were selected from among subjects with cardiovascular disorders whose hormonal thyroid status had been controlled previously and who hadn't been treated for thyroid functional disorders. Based on these criteria we defined a study lot made up of 791 subjects, 700 women and 91 men, aged between 22 to 86, with a mean age of approximately 60 years old, divided into five groups, based on the level of thyroid hormones. Once the lot was constituted, evaluations were made of the cardiovascular and thyroid condition at 6 and 12 months.
Results: During monitoring, most patients who developed atrial fibrillation were registered in the groups with manifest clinical hyperthyroidism, 34,62% and respectively with subclinical hypothyroidism, 38,6%. The main risk factors at the patients with manifest clinical hyperthyroidism were: female gender (RR=1.97) and age above 60 (RR=1.33), as well as the presence of coronary disease in the personal pathological record (RR=3.31), HBP (RR=1.46) and cardiac frequency in excess of 80 beats/min (RR=1.38). The main risk factors that led to atrial fibrillation among the patients with subclinical hypothyroidism, were: obesity (RR=2.21), the presence in the personal record of heart disease (RR=2,0), age over 60 (RR=1.90) and female sex (RR=1.30). At the patients who had been administered beta blockers prior to admission (RR=0.99), ACEI (RR=0.85) and/or antiarrythmic drugs (RR=0.54), the medication represented a protective factor against developing atrial fibrillation.
Conclusions: Thyroid dysfunctions are associated with an increased risk to develop atrial fibrillation, both in the case of clinically manifest and the subclinical manifest forms. These results support long term screening for thyroid dysfunctions for patients with atrial fibrillation.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Importance: Cardiovascular health outcomes associated with noncigarette tobacco products (cigar, pipe, and smokeless tobacco) remain unclear, yet such data are required for evidence-based regulation.
Objective: To investigate the association of noncigarette tobacco products with cardiovascular health outcomes.
Design, Setting, And Participants: This cohort study was conducted within the Cross Cohort Collaboration Tobacco Working Group by harmonizing tobacco-related data and conducting a pooled analysis from 15 US-based prospective cohorts with data on the use of at least 1 noncigarette tobacco product ranging between 1948 and 2015.
Thromboembolism Risk Profiles in Non-valvular Atrial Fibrillation: How Can Machine Learning-Based Analysis Add to Our Understanding?
J Gen Intern Med
January 2025
Northwell, 2000 Marcus Ave., Suite 300, New Hyde Park, NY, 11042-1069, USA.
Risk factors for the recurrence of atrial fibrillation after catheter ablation: a meta-analysis.
Egypt Heart J
January 2025
Department of Cardiology, Lianyungang No 1 People's Hospital, No. 6 East Zhenhua Road, Haizhou District, Lianyungang, 222061, Jiangsu, China.
Background: The rate at which atrial fibrillation (AF) patients experience a return of symptoms after catheter ablation is significant, and there are multiple risk factors involved. This research intends to perform a meta-analysis to explore the risk factors connected to the recurrence of AF in patients following catheter ablation.
Methods: The PubMed, Cochrane Library, WOS, Embase, SinoMed, CNKI, Wanfang, and VIP databases were explored for studies from January 1, 2000 to August 10, 2021, and research meeting the established inclusion requirements was chosen.
Metabolic Dysfunction Associated-Steatotic Liver Disease (MASLD) and Cardiovascular Risk: Embrace All Facets of the Disease.
Curr Cardiol Rep
January 2025
Third Department of Medicine, General University Hospital and First Faculty of Medicine, Charles University, 121 08, Prague, Czech Republic.
Purpose Of Review: In recent years, the terms "metabolic associated fatty liver disease-MAFLD" and "metabolic dysfunction-associated steatotic liver disease-MASLD" were introduced to improve the encapsulation of metabolic dysregulation in this patient population, as well as to avoid the negative/stigmatizing terms "non-alcoholic" and "fatty".
Recent Findings: There is evidence suggesting links between MASLD and coronary heart disease (CHD), heart failure (HF), atrial fibrillation (AF), stroke, peripheral artery disease (PAD) and chronic kidney disease (CKD), although the data for HF, AF, stroke and PAD are scarcer. Physicians should consider the associations between MASLD and CV diseases in their daily practice.
The Role of RyR2 Mutations in Congenital Heart Diseases: Insights Into Cardiac Electrophysiological Mechanisms.
J Cardiovasc Electrophysiol
January 2025
Department of Cardiology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
Ryanodine receptor 2 (RyR2) protein, a calcium ion release channel in the sarcoplasmic reticulum (SR) of myocardial cells, plays a crucial role in regulating cardiac systolic and diastolic functions. Mutations in RyR2 and its dysfunction are implicated in various congenital heart diseases (CHDs). Studies have shown that mutations in the RYR2 gene, which encodes the RyR2 protein, are linked to several cardiac arrhythmias, including catecholaminergic polymorphic ventricular tachycardia (CPVT), long QT syndrome (LQTS), calcium release deficiency syndrome (CRDS), and atrial fibrillation (AF).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!